Allergan Names Jim Hindman Chief Financial Officer
News Aug 21, 2014
Allergan, Inc. has announced that Jim Hindman has been named Executive Vice President, Finance and Business Development, Chief Financial Officer, effective immediately. Mr. Hindman succeeds Jeff Edwards, who after 21 years of service to Allergan, including nine years in the Chief Financial Officer role, has decided to step down from the position due to family commitments. Mr. Edwards will remain employed by Allergan in a non-executive officer capacity to facilitate a smooth transition.
Mr. Hindman joined Allergan in 1984 and has served as Senior Vice President, Treasury, Risk and Investor Relations since 2002. Prior to that, he served in a variety of finance positions, including Senior Vice President, Finance and Controller, Assistant Corporate Controller and Vice President, Financial Planning and Analysis.
Mr. Hindman also serves as President of The Allergan Foundation. Before joining Allergan, Mr. Hindman worked at Deloitte, Haskins and Sells. He has a B.S. in accounting from Loyola Marymount University, an M.B.A. from Pepperdine University and is a Certified Public Accountant (Inactive).
"For more than two decades, Jeff Edwards has fully committed his considerable talents to serving Allergan and we have been exceptionally privileged to have him as a colleague," said David E.I. Pyott, Allergan's Chairman of the Board and Chief Executive Officer. "Jeff's strong work ethic and complete dedication have defined his tenure, and his many contributions across several roles have helped build Allergan into the successful company it is today. After devoting so much time and energy to Allergan, Jeff informed me in February 2014 of his desire to commit more time to his family, and that he was therefore considering stepping down from the Chief Financial Officer position at a later point in 2014. Jeff's decision reflects his strong values, and we support him and are glad that we are able to make this transition in accordance with his wishes. On behalf of the Board of Directors and management team, I would like to thank Jeff for his service, and all of us at Allergan extend to him and his family our very best regards as they start a new chapter in their lives."
Mr. Pyott added, "We are pleased to name Jim Hindman as Allergan's Chief Financial Officer. Jim has been an instrumental member of our organization for many years, and particularly during the past few months, has played an important leadership role. We believe that Jim is ideally suited to assume the position of Chief Financial Officer and we are confident that his long tenure and experience in our finance organization, together with his strong record as a leader in the Company, will be invaluable as he assumes his new role."
"I have deeply appreciated the opportunity to serve as Allergan's Chief Financial Officer, and while in the position, fully committed myself to the role and to my team, all of our employees, stockholders and business partners," said Mr. Edwards. "The decision to step down was remarkably challenging, but I must remain true to the commitment I made to my family in early 2014."
Mr. Edwards continued, "Allergan has a strong, qualified and experienced finance team for whom I have great respect, and Jim Hindman is a talented professional and leader who is highly regarded both inside and outside of the Company. I have the utmost confidence in Jim and I know he will do a fantastic job as my successor. Allergan is an extraordinary organization that continues to perform extremely well and it has a very bright future."
Mr. Hindman added, "I am excited to take on this new role and I look forward to working with David, the Board of Directors and Allergan's talented employees as we continue our focus on delivering enhanced value to stockholders."
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE